|
Receptor BioLogix has generated product opportunities related to cancer and autoimmune disease for which it is seeking partners and collaborators. There include its Pan-HER antagonist (pan-HER ligand trap) for cancer and Tie1-IFP angiogenesis inhibitor for inflammatory disease/rheumatoid arthritis. Receptor BioLogix is also interested in discussing the application of its IFP/SCAN technology for the discovery of novel biotherapeutic candidates targeting partner-selected genes/gene families for multiple therapeutic indications.
If you are interested in exploring a partnership with Receptor BioLogix involving any of the above programs, or would like additional information, please contact:
Douglas J. Kawahara, Ph.D.
VP Business Development
650/856-4663
dkawahara@RBLX.com
|
